215 related articles for article (PubMed ID: 29136405)
1. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA
Br J Cancer; 2018 Feb; 118(3):441-447. PubMed ID: 29136405
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA
Breast Cancer Res Treat; 2018 Aug; 171(1):151-159. PubMed ID: 29736743
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).
Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA
Breast; 2018 Apr; 38():7-13. PubMed ID: 29172171
[TBL] [Abstract][Full Text] [Related]
4. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
Daniels B; Kiely BE; Tang M; Tervonen H; Pearson SA
BMC Cancer; 2019 Sep; 19(1):909. PubMed ID: 31510955
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Xu B; Hu X; Zheng H; Wang X; Zhang Q; Cui S; Liu D; Liao N; Luo R; Sun Q; Yu S
Oncotarget; 2016 Aug; 7(31):50643-50655. PubMed ID: 27276706
[TBL] [Abstract][Full Text] [Related]
7. Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly.
van Rooijen JM; de Munck L; Teeuwen GM; de Graaf JC; Jansman FG; Boers JE; Siesling S
Anticancer Drugs; 2016 Feb; 27(2):127-32. PubMed ID: 26473525
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Kaczmarek E; Saint-Martin C; Pierga JY; Brain E; Rouzier R; Savignoni A; Mouret-Fourme E; Dieras V; Piot I; Dubot C; Carton M; Lerebours F
Breast Cancer Res Treat; 2019 Dec; 178(3):505-512. PubMed ID: 31486993
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
10. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Steenbruggen TG; Bouwer NI; Smorenburg CH; Rier HN; Jager A; Beelen K; Ten Tije AJ; de Jong PC; Drooger JC; Holterhues C; Kitzen JJEM; Levin M-; Sonke GS
Breast Cancer Res Treat; 2019 Dec; 178(3):597-605. PubMed ID: 31493033
[TBL] [Abstract][Full Text] [Related]
11. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
12. Survival and cardiac toxicity in patients with HER2-positive, metastatic breast cancer treated with trastuzumab in routine clinical practice.
Vasista A; Ryan L; Naher S; Moylan E; Stockler MR; Wilcken N; Kiely BE
Asia Pac J Clin Oncol; 2020 Feb; 16(1):34-38. PubMed ID: 31657878
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Poggio F; Puglisi F; Bernardo A; Montemurro F; Poletto E; Pozzi E; Rossi V; Risi E; Lai A; Zanardi E; Sini V; Ziliani S; Minuti G; Mura S; Grasso D; Fontana A; Del Mastro L
Oncologist; 2015 Aug; 20(8):880-9. PubMed ID: 26099741
[TBL] [Abstract][Full Text] [Related]
14. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
[TBL] [Abstract][Full Text] [Related]
15. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
17. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
18. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Le Du F; Carton M; Bachelot T; Saghatchian M; Pistilli B; Brain E; Loirat D; Vanlemmens L; Vermeulin T; Emile G; Gonçalves A; Ung M; Robert M; Jaffre A; Desmoulins I; Jouannaud C; Uwer L; Marc Ferrero J; Mouret-Reynier MA; Jacot W; Chevrot M; Delaloge S; Diéras V
Oncologist; 2023 Oct; 28(10):e867-e876. PubMed ID: 37589218
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.
Ban M; Viculin J; Tomic S; Capkun V; Strikic A; Mise BP; Utrobicic I; Vrdoljak E
Neoplasma; 2016; 63(5):761-7. PubMed ID: 27468880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]